BCMA72-80

CAS No. 2293841-58-2

BCMA72-80( —— )

Catalog No. M30504 CAS No. 2293841-58-2

BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    BCMA72-80
  • Note
    Research use only, not for human use.
  • Brief Description
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
  • Description
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2293841-58-2
  • Formula Weight
    1196.55
  • Molecular Formula
    C59H97N13O11S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:Tyr-Leu-Met-Phe-Leu-Leu-Arg-Lys-Ile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Bae J, et al. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 Mar 12.
molnova catalog
related products
  • N6-(p-Hydroxypheneth...

    N6-(p-Hydroxyphenethyl)-Adenosine) is an adenosine analogue.

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?

  • Cannabichromenic aci...

    Cannabichromenic acid is a new antibiotic active against gram-positive bacteria, including MRSA.